Nuvation Bio (NUVB) Chief Medical Officer reports 150K share sale and option exercise

Rhea-AI Filing Summary

Nuvation Bio Inc. reported insider equity transactions by its Chief Medical Officer. On 12/01/2025, the officer exercised stock options to acquire 150,000 shares of Class A common stock at an exercise price of $2.93 per share. On the same date, the officer sold 150,000 shares of Class A common stock in an open-market transaction with a weighted-average sales price of $7.8217 per share, with individual sale prices ranging from $7.80 to $7.855.

After these transactions, the officer beneficially owned 18,000 shares of Class A common stock directly and held 165,000 stock options that remain outstanding, each option relating to Class A common stock. The option originally covered 150,000 shares, vested 25% after one year from 08/29/2022 and monthly over the following 36 months, conditioned on continued service.

Insider Trade Summary

Net Seller: 150,000 shares ($1,173,255)

Net Sell 3 txns

Insider Liu Dongfang

Role CHIEF MEDICAL OFFICER

Sold 150,000 shs ($1.17M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	150,000	$0.00	--
Exercise	Class A Common Stock	150,000	$2.93	$440K
Sale	Class A Common Stock	150,000	$7.8217	$1.17M

Holdings After Transaction: Stock Option (Right to Buy) — 165,000 shares (Direct); Class A Common Stock — 168,000 shares (Direct)

Footnotes (1)

1. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.80 to $7.855. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Option vested as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/03/2025 - 05:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Liu Dongfang

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	12/01/2025		M		150,000	A	$2.93	168,000	D
Class A Common Stock	12/01/2025		S		150,000	D	$7.8217(1)	18,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.93	12/01/2025		M			150,000	(2)	08/28/2032	Class A Common Stock	150,000	$0	165,000	D

Explanation of Responses:

1. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.80 to $7.855. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

2. Option vested as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date

	/s/ Stephen Dang, Attorney-in-Fact	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nuvation Bio (NUVB) disclose?

Nuvation Bio disclosed that its Chief Medical Officer exercised stock options for 150,000 Class A common shares at $2.93 per share and sold 150,000 shares in the market on 12/01/2025.

At what prices did the Nuvation Bio (NUVB) insider sell shares?

The insider reported a weighted-average sales price of $7.8217 per share, with individual trades executed between $7.80 and $7.855 per share.

How many Nuvation Bio (NUVB) shares does the insider own after the transaction?

Following the reported transactions, the officer directly owned 18,000 shares of Nuvation Bio Class A common stock and held 165,000 stock options.

What stock option grant did the Nuvation Bio (NUVB) Form 4 describe?

The Form 4 describes a stock option with an exercise price of $2.93 covering 150,000 shares of Class A common stock, with an expiration date of 08/28/2032.

How does the Nuvation Bio (NUVB) option vesting schedule work for this grant?

The option vested as to 25% on the one-year anniversary of 08/29/2022, then vested monthly over the next 36 months, subject to the officer’s continuous service.

What is the insider’s role at Nuvation Bio (NUVB)?

The reporting person is an officer of Nuvation Bio Inc., serving as the company’s Chief Medical Officer.